People with multiple sclerosis (MS) who are diagnosed with colorectal cancer may be at a higher risk of dying from cancer or other causes over the next six months to one year than people with colorectal cancer who do not have MS, according to a study published in the September 15, 2021, online issue of Neurology®, the medical journal of the American Academy of Neurology.
New research shows that Multiple Sclerosis (MS) patients undergoing anti-CD20 (aCD20) treatment – which depletes the B cells that contribute to the MS attacks – are able to mount robust T-cell responses to the mRNA COVID-19 vaccines, despite having a muted antibody response to the vaccines.
Patients with newly diagnosed multiple sclerosis report several symptoms – pain, fatigue, depression and anxiety – in the first year. A significant number of them experience a cluster of two or more of those symptoms, according to a new study from Michigan Medicine.
Finding treatments for advanced multiple sclerosis (MS) has been difficult. But new research may help neurologists identify which drugs are best for people with the advanced form of MS called secondary progressive MS. The new study, published in the June 30, 2021, online issue of Neurology®, the medical journal of the American Academy of Neurology, found that the more potent disease-modifying drugs are more effective in reducing flare-ups in secondary progressive MS than the less potent drugs that tend to be safer to take. However, the researchers found no difference in how fast the disease progressed between these two types of drugs.
A new study suggests that even when differences in socioeconomic status are taken into consideration, Black people with multiple sclerosis (MS) may be more negatively impacted by the disease than white people with MS. The research is published in the June 30, 2021, online issue of Neurology®, the medical journal of the American Academy of Neurology. The study found that Black people with MS had lower scores on certain measures of neurological health, like dexterity and walking tests and showed more evidence of disease progression on brain scans.
One-quarter of people who take the drug methotrexate for common immune system disorders — from rheumatoid arthritis to multiple sclerosis — mount a weaker immune response to a COVID-19 vaccine, a new study shows.
A new University of California, Irvine-led study finds low serum levels of the sugar N-acetylglucosamine (GlcNAc), is associated with progressive disability and neurodegeneration in multiple sclerosis (MS).
As average temperatures around the globe climb, a preliminary study has found people with multiple sclerosis (MS) may expect worsening symptoms, enough to send them to the hospital more often. The preliminary study released today, March 2, 2021, will be presented at the American Academy of Neurology’s 73rd Annual Meeting being held virtually April 17 to April 22, 2021.
No matter where you are in the world, the 2021 AAN Annual Meeting is one click away. Journalists can now register to attend the 73rd Annual Meeting of the American Academy of Neurology (AAN) being held virtually April 17-22, 2021. The AAN Annual Meeting is the world’s largest gathering of neurologists who come together to share the latest advances in neurologic research.
Essential for bone health, immune response and even memory and thinking, vitamin D may also be linked to preventing severe COVID-19 symptoms.
A new study shows that intense immunosuppression followed by a hematopoietic stem cell transplant may prevent disability associated with multiple sclerosis (MS) from getting worse in 71% of people with relapsing-remitting MS for up to 10 years after the treatment. The research is published in the January 20, 2021, online issue of Neurology®, the medical journal of the American Academy of Neurology. The study also found that in some people their disability improved over 10 years after treatment. Additionally, more than half of the people with the secondary progressive form of MS experienced no worsening of their symptoms 10 years after a transplant.
People with the advanced form of multiple sclerosis (MS) called secondary progressive MS who took the drug siponimod for one to two years had improved cognitive processing speed compared to those who did not take the drug, according to a new study published in the December 16, 2020, online issue of Neurology®, the medical journal of the American Academy of Neurology.
People with multiple sclerosis (MS) may not be at higher risk of developing two of the three cancers that occur most commonly in people with MS, breast and colorectal cancer, than people who don’t have the disease, according to a new study published in the November 25, 2020, online issue of Neurology®, the medical journal of the American Academy of Neurology. However, the study did find that people with MS had a higher incidence of bladder cancer.
Monitoring how patients with multiple sclerosis or other degenerative diseases use their smartphones could provide valuable information to help get them better treatment. In the journal Chaos, researchers used an app to record the keystroke dynamics of a control group and those of subjects in various stages of MS treatment. In doing so, they observed changes in the way people with MS typed that were not seen in subjects who did not have the disease.
Jefferson researchers develop an approach to specifically impede the autoimmune response that drives the disease, while leaving the rest of the immune system fully functioning.
Researchers uncover defining features of a subset of T-cells that may drive autoimmunity in MS, and could prove to be a new target for therapy.
Brain cell dysfunction in low oxygen is, surprisingly, caused by the very same responder system that is intended to be protective, according to a new published study by a team of researchers at the Case Western Reserve University School of Medicine.
University at Buffalo researchers have received a $957,000 grant from the U.S. Army Medical Research and Development Command to explore the progression of neurodegeneration in multiple sclerosis (MS).
An up-and-coming gene therapy for blood disorders. A new class of medications for cystic fibrosis. Increased access to telemedicine. These are some of the innovations that will enhance healing and change healthcare in the coming year, according to a distinguished panel of clinicians and researchers from Cleveland Clinic.
In conjunction with the 2020 Medical Innovation Summit, Cleveland Clinic announced the Top 10 Medical Innovations for 2021.
Background: Risk factors previously identified for worse outcomes with SARS-CoV-2 infections include older age, male sex and specific comorbid conditions. An increased risk for poorer COVID-19 outcomes in people with multiple sclerosis (MS) are similar to the general population, but…
Background: The Coronavirus Disease 2019 (COVID-19) pandemic has introduced uncertainties into the multiple sclerosis (MS) community and the focus so far has been the severity of infection among people with MS (pwMS) who have COVID-19. This approach has left questions…
Background: Pregnancy in MS typically goes along with reduced disease activity in the third trimester, followed by an increase in relapse frequency postpartum. Neurofilament light chain levels in serum (NfL) is a specific biomarker of neuroaxonal injury. Increased NfL levels…
Background: Commensal gut microbes are known to affect host immune function and may be modifiable. Recent work suggests gut microbiota composition contributes to onset of MS; however, little is known about its contribution to MS disease activity. Objectives: Estimate the…
Background: Retinoid acid X receptor [RXR] gamma agonists promote oligodendrocyte progenitor cell differentiation and remyelination following experimental demyelination. Objectives: To assess the safety and efficacy of bexarotene, a non-specific RXR agonist licensed for cutaneous T-cell lymphoma, as a remyelinating therapy…
Background: Risk factors associated with the severity of COVID-19 in patients with multiple sclerosis (MS) begin to be identified from several cohort studies. Disease modifying therapies (DMTs) may modify the risk of developing a severe COVID-19 infection, beside identified risk…
Background: Limited evidence-based data exist on potential risks of COVID-19 infection in persons with multiple sclerosis (pwMS) receiving immunotherapy. More than 160,000 pwMS have been treated with ocrelizumab (OCR), in clinical trial and real-world settings; data continue to show a…
Background: As the COVID-19 pandemic amplifies, efforts to minimise the risk on vulnerable people are essential. People with multiple sclerosis (MS) may be a vulnerable group due to the high proportion taking long-term immunosuppressive disease-modifying therapies (DMTs). Studies from Italy…
In a new University of California, Irvine-led study, researchers have discovered how regulatory T cells (Treg) are instrumental in limiting the damage caused to the spinal cord in diseases like multiple sclerosis (MS).
A new study from Harvey L. Neiman Health Policy Institute finds that over ¾ of Multiple Sclerosis (MS) patients face financial toxicity that often results in non-adherence to follow up care. This Multiple Sclerosis Journal study is the first of its kind to evaluate financial toxicity in MS patients and whether financial hardship is linked to patients foregoing the therapy and imaging follow-up prescribed in their treatment plan.
DALLAS – Aug. 12, 2020 – In an animal model of multiple sclerosis (MS), decreasing the amount of a protein made in the liver significantly protected against development of the disease’s characteristic symptoms and promoted recovery in symptomatic animals, UTSW scientists report.
Registered media to MSVirtual2020 will have access to the full program including plenary sessions, invited speakers and platform presentations of abstracts, poster presentations, teaching courses, and industry supported satellite symposia, both scheduled and on-demand
A blood test may help predict which people with multiple sclerosis (MS) will get worse during the following year, according to a study published in the May 20, 2020, online issue of Neurology®, the medical journal of the American Academy of Neurology.
Ursolic acid, abundant in fruit peels and some herbs, both prevents and repairs neurons in animal models of multiple sclerosis.
Researchers used a virtual reality system to trick subjects into thinking they were falling as they walked on a treadmill, finding clear differences in reactions between people with multiple sclerosis and people without. These differences were not evident without the “falling” illusion.
Nationally-known developer Chris Jeffries and his wife Lisa have donated $25 million to Henry Ford Health System, the largest single gift from an individual in the health system’s 105-year history. This historic gift will rapidly accelerate the growth and expansion of Henry Ford’s Precision Medicine program, with the ultimate goal of creating a Precision Health Center. The efforts will have a robust focus on the advancement of cancer research and treatment, while also expanding to other medical specialties treating behavioral health, cardiovascular and metabolic diseases.
Changing global temperatures could mean lost productivity for workers around the globe, according to Nancy Sicotte, MD, chair of the Department of Neurology at Cedars-Sinai.
The naturally occurring molecule N-acetylcysteine (NAC) shows benefit in a clinical trial for multiple sclerosis.
Dr. Francisco J. Quintana to receive the award and deliver the Barancik Prize lecture at the ACTRIMS Forum 2020 for work resulting in new tools and treatments to combat MS
Dr. Peter Calabresi, professor of Neurology and Neuroscience at the Johns Hopkins School of Medicine and Director of the Johns Hopkins Multiple Sclerosis (MS) Center, will present his team’s discovery of a possible link between severe damage and C3 and C1q gene variants, and how this information could lead to improvements in the ways MS and other neurodegenerative diseases are treated, during his keynote Kenneth P. Johnson Memorial Lecture on the opening day of the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2020.
A molecular switch has the ability to turn on a substance in animals that repairs neurological damage in disorders such as multiple sclerosis (MS), Mayo Clinic researchers discovered.
A new online program can help patients receive behavioral health care for chronic pain, fatigue and depressed mood from the comfort of their home.
Measuring changes in the speed of electrical signals along nerves connecting the eyes to the brain may accurately reflect recovery from myelin loss in multiple sclerosis (MS), according to researchers at the University of Wisconsin–Madison, and could be used to evaluate new treatments for the disease.
Approximately 1,200 researchers and clinicians are expected to attend the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual Forum Feb. 27-29, 2020, in West Palm Beach, Florida.
For people with many neurologic disorders, seeing the neurologist by video may be as effective as an in-person visit, according to a review of the evidence conducted by the American Academy of Neurology (AAN). The evidence review examined all available studies on use of telemedicine for several neurologic conditions – stroke being one of the conditions that is well-validated and highly utilizes telemedicine – and is published in the December 4, 2019, online issue of Neurology®, the medical journal of the AAN. The results indicate that a diagnosis from a neurologist by video for certain neurologic conditions is likely to be as accurate as an in-person visit.
In a finding that could help lead to new therapies for immune diseases like multiple sclerosis and IBD, scientists report in the Journal of Experimental Medicine identifying a gene and family of proteins critical to the formation of mature and fully functioning T cells in the immune system.
In a decade, Medicare recipients saw a sevenfold increase in out of pocket costs for multiple sclerosis drugs. Spending on these drugs by Medicare itself increased by tenfold.